Aldeyra Therapeutics, Inc. (ALDX) Thursday said that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted New Drug Application (NDA) for reproxalap for the treatment of dry eye disease.
Prescription Drug User Fee Act (PDUFA) target action date, the date on which a decision from the regulator is expected, is December 16, 2025.
"Based on the FDA's requirement for an additional clinical trial demonstrating the efficacy of reproxalap in treating the symptoms of dry eye disease, and per agreement with the FDA, the NDA resubmission contained a single clinical trial that achieved the primary endpoint of reducing ocular discomfort relative to the vehicle control," stated Todd C. Brady, President and Chief Executive Officer of Aldeyra.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.